Pharmacy Grand Rounds
Staying PrEPped: Modern Prevention of HIV

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST) Originating from Eau Claire WI-EU-LH-B-1104

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

Emtricitabine/tenofovir alafenamide, which is nearly identical to emtricitabine/tenofovir disoproxil fumurate, is an antiretroviral used in combination with other antivirals for the treatment of HIV-1. Emtricitabine/tenofovir alafenamide indications were expanded in October of 2019, through FDA approval as a first line agent for pre-exposure prophylaxis (PrEP). Historically, emtricitabine/tenofovir disoproxil fumurate has been the drug of choice. This presentation will review the new recommendations regarding antiretroviral therapies in PrEP and discuss emerging evidence surrounding the use of an investigative long-acting injectable medication.

At the conclusion of this knowledge-based CE session, participants should be able to:

• Outline the pharmacologic profile of emtricitabine/tenofovir disoproxil fumurate to emtricitabine/tenofovir alafenamide
• Describe potential candidates for pre-exposure prophylaxis according to the Centers for Disease Control
• Discuss emerging evidence for a long-acting injectable medication for pre-exposure prophylaxis

Session Announcement

Session Slides

FACULTY INFORMATION

Zakari S. Agherrabi, PharmD
PGY1 Pharmacy Resident
Mayo Clinic Health System - Eau Claire, WI

Zakari received a Doctor of Pharmacy from the Medical College of Wisconsin School of Pharmacy in Milwaukee, WI.  He is a current PGY1 Pharmacy Resident at Mayo Clinic Health Systems – Eau Claire with clinical practice interests in critical care and emergency medicine. 

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Zakari S. Agherrabi, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Cabotegravir

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS